← Eichor
Condition: Advanced Hodgkin Lymphoma Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Advanced Hodgkin Lymphoma

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Swedish Cardiac And Renal Failure Study-1
Phase 2 · 1 location(s) · Karolinska Institutet · NCT07029503An Engineered Sirpα Fused to Anti-Pd-L1 And Tgf-β Fusion Protein (HCB301) in Subjects With Selected Advanced Tumors
Phase 1 · 7 location(s) · FBD Biologics Limited · NCT06487624Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies
Phase 1/Phase 2 · 39 location(s) · CellCentric Ltd. · NCT04068597IKS03 in Patients With Advanced B Cell Non-Hodgkin Lymphomas
Phase 1 · 13 location(s) · Iksuda Therapeutics Ltd. · NCT05365659A Phase 1 of CTX-8371 in Patients With Advanced Malignancies
Phase 1 · 10 location(s) · Compass Therapeutics · NCT06150664Evaluation of Skin Tests in Biotherapy Allergies
NA · 1 location(s) · University Hospital, Angers · NCT06971848Fixed-Duration Zanubrutinib, Bendamustine, and Obinutuzumab (ZBG) in Treatment-Naïve Advanced Stage Follicular Lymphoma
NA · 1 location(s) · The First Affiliated Hospital with Nanjing Medical Universit · NCT07126678Personalized Reduction of Chemotherapy Intensity Through ctDNA Evaluation for the Treatment of Patients With Advanced Ho
Phase 2 · 6 location(s) · University of Washington · NCT06745076A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
Phase 1/Phase 2 · 68 location(s) · Turning Point Therapeutics, Inc. · NCT04094610PET-Adapted First-Line Therapy With Nivolumab for Advanced Hodgkin Lymphoma
Phase 2 · 1 location(s) · National Research Center for Hematology, Russia · NCT07209059Study Evaluating ISM8207 in Participants With Advanced Solid Tumors and Relapsed/Refractory B-Cell Lymphoma
Phase 1 · 4 location(s) · InSilico Medicine Hong Kong Limited · NCT06445517Chemoimmunotherapy and Allogeneic Stem Cell Transplant for NK T-cell Leukemia/Lymphoma
EARLY_Phase 1 · 6 location(s) · New York Medical College · NCT03719105The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies
Phase 1/Phase 2 · 11 location(s) · AVM Biotechnology Inc · NCT04329728Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)
Phase 1 · 2 location(s) · Baylor College of Medicine · NCT01853631Trial to Evaluate the Safety & Tolerability of JBZ-001 in Pts With Advanced Solid and Hematological Malignancies
Phase 1 · 2 location(s) · Jabez Bioscience, Inc · NCT06801002A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients
Phase 1 · 16 location(s) · OncoNano Medicine, Inc. · NCT06022029Study of AXT-1003 in Subjects With Advanced Malignant Tumors.
Phase 1 · 5 location(s) · Axter Therapeutics (Beijing) Co., Ltd · NCT06484985BrECADD Therapy in Stage 2 B-IV Hodgkin Lymphoma
Phase 2 · 1 location(s) · University of Miami · NCT07002216BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)
Phase 1/Phase 2 · 25 location(s) · BioInvent International AB · NCT04752826TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumo
Phase 2 · 181 location(s) · American Society of Clinical Oncology · NCT02693535Testing Addition of an Anti-cancer Drug, Vorasidenib to Temozolomide, After Radiation for Advanced Brain Cancer
Phase 3 · 82 location(s) · Alliance for Clinical Trials in Oncology · NCT07215910Comparison of AVD + Low-Dose Nivolumab vs. PET-Adapted BEACOPP-like in Advanced cHL
Phase 2 · 3 location(s) · St. Petersburg State Pavlov Medical University · NCT07234487Clinical Study of XPO1 Inhibitor Selinexor Combined With COPL in Newly Diagnosed Advanced NK/T-cell Lymphoma
Phase 2 · 1 location(s) · Chinese PLA General Hospital · NCT05833893Study Evaluating Safety Pharmacokinetics and Pharmacodynamics of AUR112 in Patients With Relapsed Advanced Lymphoma
Phase 1 · 19 location(s) · Aurigene Discovery Technologies Limited · NCT06755450Multilayer Biological Characterization of Advanced Follicular Lymphoma: a Translational Study From FIL_FOLL12 Trial
Phase N/A · 26 location(s) · Fondazione Italiana Linfomi - ETS · NCT05816850A Study of PEP07 (Checkpoint Kinase 1 Inhibitor) in Patients With Advanced Cancer
Phase 1 · 5 location(s) · PharmaEngine · NCT05659732IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers
Phase 1/Phase 2 · 12 location(s) · Indapta Therapeutics, INC. · NCT06119685Pianzumab Combined With AVD Regimen in the Treatment of Newly-diagnosed Advanced Classic Hodgkin Lymphoma
Phase 2 · 1 location(s) · Sun Yat-sen University · NCT05949931Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors
Phase 1/Phase 2 · 1 location(s) · Essen Biotech · NCT07410494A Study to Investigate the Safety and Tolerability of SCR-6920 Capsule in Patients With Advanced Malignant Tumors
Phase 1 · 1 location(s) · Jiangsu Simcere Pharmaceutical Co., Ltd. · NCT05528055
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.